FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149164490> ?p ?o ?g. }

• W2149164490 endingPage "1188" @default.
• W2149164490 startingPage "1175" @default.
• W2149164490 abstract "Many tumor cells specifically overexpress somatostatin receptors, in particular, subtype 2 (SSTR2). Lanreotide, a somatostatin analogue with high affinity for SSTR2, can be exploited as a ligand for tumor targeted therapy. In this study, lanreotide was first conjugated to poly(ethylene glycol)-b-poly(ε-caprolactone) (PEG-b-PCL) copolymer, and the active targeting micelles with paclitaxel (lanreotide-PM-PTX) or fluorescent agent were constructed and characterized with various analytical methods. Lanreotide-PM-PTX micelles were spherical in shape with a hydrodynamic diameter of 43.2 ± 0.4 nm, high drug encapsulation (87.1 ± 2.8%) and slow drug release rate. Two cancer cell lines (human lung cancer H446 and human breast cancer MCF-7 cells) with different expression levels of SSTR2 were used in this study. As observed by flow cytometry, confocal microscopy and cytotoxicity studies, lanreotide-encoded PEG-b-PCL micelles demonstrated more specific cell uptake and cytotoxicity in SSTR2-positive tumor cells via a receptor-mediated mechanism over the passive targeting micelles. The active targeting micelles showed higher accumulation in tumor tissue and tumor cells in tumor-bearing mice in vivo by near-infrared fluorescence (NIRF) imaging, high-performance liquid chromatography and confocal microscopy, respectively. Furthermore, treatment with lanreotide-PM-PTX micelles resulted in stronger tumor inhibition, increased life span and enhanced tumor cell apoptosis in SSTR2-overexpressing tumor model in athymic nude mice. The in vivo efficacy test with both H446 and MCF-7 tumor models further demonstrated the involvement of receptor-mediated interaction. Finally, the active targeting micelles exhibited less body weight loss, lower hemolysis and lower myelosuppression, as compared with the control groups. In conclusion, lanreotide can serve as an effective homing peptide, and the lanreotide-modified PEG-b-PCL micelles hold considerable promise in the treatment of SSTR2-overexpressing solid tumors." @default.
• W2149164490 created "2016-06-24" @default.
• W2149164490 creator A5000168358 @default.
• W2149164490 creator A5002362678 @default.
• W2149164490 creator A5007785866 @default.
• W2149164490 creator A5008302058 @default.
• W2149164490 creator A5016622484 @default.
• W2149164490 creator A5022541493 @default.
• W2149164490 creator A5039837606 @default.
• W2149164490 creator A5043866674 @default.
• W2149164490 creator A5056450584 @default.
• W2149164490 creator A5079412241 @default.
• W2149164490 creator A5086388928 @default.
• W2149164490 date "2012-03-30" @default.
• W2149164490 modified "2023-09-27" @default.
• W2149164490 title "A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel to the Tumors with Overexpression of Somatostatin Receptors" @default.
• W2149164490 cites W1636022800 @default.
• W2149164490 cites W1644509372 @default.
• W2149164490 cites W1662084969 @default.
• W2149164490 cites W1845781803 @default.
• W2149164490 cites W1901625798 @default.
• W2149164490 cites W1966418307 @default.
• W2149164490 cites W1967785970 @default.
• W2149164490 cites W1967810569 @default.
• W2149164490 cites W1977533639 @default.
• W2149164490 cites W1988754095 @default.
• W2149164490 cites W1994118792 @default.
• W2149164490 cites W2001850555 @default.
• W2149164490 cites W2003928619 @default.
• W2149164490 cites W2007861578 @default.
• W2149164490 cites W2011590818 @default.
• W2149164490 cites W2011742960 @default.
• W2149164490 cites W2014096936 @default.
• W2149164490 cites W2016141648 @default.
• W2149164490 cites W2016156919 @default.
• W2149164490 cites W2016825334 @default.
• W2149164490 cites W2016843203 @default.
• W2149164490 cites W2019639857 @default.
• W2149164490 cites W2021465707 @default.
• W2149164490 cites W2024862077 @default.
• W2149164490 cites W2026687778 @default.
• W2149164490 cites W2028893730 @default.
• W2149164490 cites W2030567407 @default.
• W2149164490 cites W2032945008 @default.
• W2149164490 cites W2035838854 @default.
• W2149164490 cites W2039460274 @default.
• W2149164490 cites W2045681528 @default.
• W2149164490 cites W2048256802 @default.
• W2149164490 cites W2053122338 @default.
• W2149164490 cites W2057632167 @default.
• W2149164490 cites W2060568174 @default.
• W2149164490 cites W2060932360 @default.
• W2149164490 cites W2063414742 @default.
• W2149164490 cites W2063671183 @default.
• W2149164490 cites W2070840273 @default.
• W2149164490 cites W2077715063 @default.
• W2149164490 cites W2079184456 @default.
• W2149164490 cites W2080232093 @default.
• W2149164490 cites W2082246436 @default.
• W2149164490 cites W2082587127 @default.
• W2149164490 cites W2083125338 @default.
• W2149164490 cites W2083349615 @default.
• W2149164490 cites W2090458975 @default.
• W2149164490 cites W2095747324 @default.
• W2149164490 cites W2099797949 @default.
• W2149164490 cites W2102853315 @default.
• W2149164490 cites W2109689528 @default.
• W2149164490 cites W2110651692 @default.
• W2149164490 cites W2122132160 @default.
• W2149164490 cites W2122359067 @default.
• W2149164490 cites W2141395077 @default.
• W2149164490 cites W2153957030 @default.
• W2149164490 cites W2159239273 @default.
• W2149164490 cites W2159334966 @default.
• W2149164490 cites W2160064249 @default.
• W2149164490 cites W2332400161 @default.
• W2149164490 cites W77345513 @default.
• W2149164490 doi "https://doi.org/10.1021/mp200464x" @default.
• W2149164490 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22435704" @default.
• W2149164490 hasPublicationYear "2012" @default.
• W2149164490 type Work @default.
• W2149164490 sameAs 2149164490 @default.
• W2149164490 citedByCount "41" @default.
• W2149164490 countsByYear W21491644902013 @default.
• W2149164490 countsByYear W21491644902014 @default.
• W2149164490 countsByYear W21491644902015 @default.
• W2149164490 countsByYear W21491644902016 @default.
• W2149164490 countsByYear W21491644902017 @default.
• W2149164490 countsByYear W21491644902018 @default.
• W2149164490 countsByYear W21491644902019 @default.
• W2149164490 countsByYear W21491644902021 @default.
• W2149164490 countsByYear W21491644902022 @default.
• W2149164490 countsByYear W21491644902023 @default.
• W2149164490 crossrefType "journal-article" @default.
• W2149164490 hasAuthorship W2149164490A5000168358 @default.
• W2149164490 hasAuthorship W2149164490A5002362678 @default.
• W2149164490 hasAuthorship W2149164490A5007785866 @default.
• W2149164490 hasAuthorship W2149164490A5008302058 @default.

• next